These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12888131)

  • 41. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
    Kuwajima I
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
    [No Abstract]   [Full Text] [Related]  

  • 42. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
    Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
    Johnson K; Oparil S; Davis BR; Tereshchenko LG
    J Am Heart Assoc; 2019 Apr; 8(8):e011961. PubMed ID: 30943832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial.
    Whittle J; Yamal JM; Williamson JD; Ford CE; Probstfield JL; Beard BL; Marginean H; Hamilton BP; Suhan PS; Davis BR;
    BMC Health Serv Res; 2016 Jul; 16():236. PubMed ID: 27391223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A specialist in clinical hypertension critiques ALLHAT.
    Meltzer JI
    Am J Hypertens; 2003 May; 16(5 Pt 1):416-20. PubMed ID: 12745205
    [No Abstract]   [Full Text] [Related]  

  • 47. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Pressel S; Davis BR; Louis GT; Whelton P; Adrogue H; Egan D; Farber M; Payne G; Probstfield J; Ward H;
    Control Clin Trials; 2001 Dec; 22(6):674-86. PubMed ID: 11738123
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].
    Slany J
    Wien Klin Wochenschr; 2003 Mar; 115(5-6):149-51. PubMed ID: 12741071
    [No Abstract]   [Full Text] [Related]  

  • 49. The ALLHAT trial: strengths and limitations.
    Fagard RH
    J Hypertens; 2003 Feb; 21(2):229-32. PubMed ID: 12569242
    [No Abstract]   [Full Text] [Related]  

  • 50. ALLHAT: still providing correct answers after 7 years.
    Einhorn PT; Davis BR; Wright JT; Rahman M; Whelton PK; Pressel SL;
    Curr Opin Cardiol; 2010 Jul; 25(4):355-65. PubMed ID: 20520537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ALLHAT and beyond.
    Alderman MH
    Am J Hypertens; 2003 Jun; 16(6):512-4. PubMed ID: 12799104
    [No Abstract]   [Full Text] [Related]  

  • 52. The ALLHAT trial: a verdict or a challenge?
    Zanchetti A; Mancia G
    J Hypertens; 2003 Feb; 21(2):223. PubMed ID: 12569240
    [No Abstract]   [Full Text] [Related]  

  • 53. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
    Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
    J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Cushman WC; Ford CE; Einhorn PT; Wright JT; Preston RA; Davis BR; Basile JN; Whelton PK; Weiss RJ; Bastien A; Courtney DL; Hamilton BP; Kirchner K; Louis GT; Retta TM; Vidt DG;
    J Clin Hypertens (Greenwich); 2008 Oct; 10(10):751-60. PubMed ID: 19090876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.
    Dewland TA; Soliman EZ; Davis BR; Magnani JW; Yamal JM; Piller LB; Haywood LJ; Alonso A; Albert CM; Marcus GM;
    JAMA Intern Med; 2016 Aug; 176(8):1085-92. PubMed ID: 27367818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. All hats off to ALLHAT: a massive study with clear messages.
    Chalmers J
    J Hypertens; 2003 Feb; 21(2):225-8. PubMed ID: 12569241
    [No Abstract]   [Full Text] [Related]  

  • 58. Comments on the renal aspects of the ALLHAT study.
    Ruilope LM
    J Hypertens; 2003 Feb; 21(2):235-6. PubMed ID: 12569244
    [No Abstract]   [Full Text] [Related]  

  • 59. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Guidelines for antihypertensive treatment: an update after the ALLHAT study.
    Salvetti A; Ghiadoni L
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S51-4. PubMed ID: 14684673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.